First Author: A.Akinci TURKEY
Co Author(s): O. Muftuoglu
Purpose:
To evaluate the results of intravitreal bevacizumab injection in patients with macular edema after uncomplicated cataract surgery.
Setting:
kudret eye hospital
Methods:
The records of 16 patients with pseudophakic macular edema due to uncomplicated cataract surgery who were treated with one intravitreal injection of 1.25 mg of bevacizumab were retrospectively evaluated. Best corrected visual acuity, intraocular pressure and central macular thickness evaluated by spectral optical coherence tomography were noted in each visit.
Results:
The follow-up was 3 months. All eyes had improved best corrected visual acuity (BCVA). The mean initial BCVA was 0.32±0.15 (0.2 to 0.5) while it was 0.5±0.24 (SD) (0,5-0,8), 0.6±0.19 (SD) (0,4-0,7) at 1 and 3 months after the injection, respectively. The BCVA levels recorded at 1st and 3 months after the surgery were significantly higher than the initial BCVA (p=0<.001). The mean initial CMT was 511.5±123.6 microns while it was 255.7±87.2 and 256.5±60.3 at 1 and 3 months after the surgery, respectively. The CMT values recorded at 1st and 3 months after the surgery were significantly lower than the initial CMT (p<0.001, p<0.001). No ocular or systemic adverse events were observed.
Conclusions:
Short-term results suggest that intravitreal bevacizumab is effective and safe in patients with pseudophakic macular edema. The treatment provides a significant improvement in best corrected visual acuity and decrease in macular thickness in eyes with pseudophakic macular edema. FINANCIAL DISCLOSURE?: No
Please wait while information is loading.
